Atyr Pharma Inc. (NASDAQ:LIFE)’s share price dropped 1.3% during trading on Thursday . The company traded as low as $2.94 and last traded at $3.02, with a volume of 1,003,159 shares traded. The stock had previously closed at $3.06.

LIFE has been the topic of a number of analyst reports. Zacks Investment Research upgraded Atyr Pharma from a “sell” rating to a “buy” rating and set a $3.50 price objective on the stock in a research report on Tuesday, May 31st. BMO Capital Markets reiterated a “hold” rating on shares of Atyr Pharma in a research report on Thursday, May 12th. Finally, William Blair downgraded Atyr Pharma from an “outperform” rating to a “market perform” rating in a research report on Thursday, March 31st. Four research analysts have rated the stock with a hold rating and one has given a buy rating to the company. Atyr Pharma has a consensus rating of “Hold” and an average target price of $23.75.

The firm’s 50 day moving average price is $2.91 and its 200 day moving average price is $4.20. The stock’s market capitalization is $70.11 million.

Atyr Pharma (NASDAQ:LIFE) last announced its earnings results on Wednesday, May 11th. The company reported ($0.68) EPS for the quarter, beating analysts’ consensus estimates of ($0.70) by $0.02. Equities analysts predict that Atyr Pharma Inc. will post ($2.79) EPS for the current fiscal year.

In related news, insider Grove Matsuoka bought 12,412 shares of the stock in a transaction on Wednesday, May 11th. The shares were purchased at an average price of $3.04 per share, for a total transaction of $37,732.48. Following the acquisition, the insider now owns 2,412 shares in the company, valued at $7,332.48. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

aTyr Pharma, Inc is a clinical-stage biotherapeutics company. The Company is engaged in the discovery and clinical development of medicines for patients suffering from severe, rare diseases using its Physiocrine biology, a discovered set of physiological modulators. The Company focuses on the development of Physiocrine-based therapeutics for the treatment of rare diseases, including facioscapulohumeral muscular dystrophy (FSHD) and limb-girdle muscular dystrophy (LGMD) 2B.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.